nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—vagus nerve—stomach cancer	0.149	0.633	CbGeAlD
Fosaprepitant—TACR1—hematopoietic system—stomach cancer	0.0244	0.103	CbGeAlD
Fosaprepitant—TACR1—smooth muscle tissue—stomach cancer	0.0215	0.0911	CbGeAlD
Fosaprepitant—TACR1—digestive system—stomach cancer	0.017	0.0719	CbGeAlD
Fosaprepitant—TACR1—endocrine gland—stomach cancer	0.014	0.0594	CbGeAlD
Fosaprepitant—TACR1—lymph node—stomach cancer	0.00969	0.0411	CbGeAlD
Fosaprepitant—TACR1—G alpha (q) signalling events—KISS1R—stomach cancer	0.00485	0.0289	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—KISS1R—stomach cancer	0.00479	0.0286	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.00434	0.0259	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—AGTR2—stomach cancer	0.00428	0.0255	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—LGALS3—stomach cancer	0.0034	0.0203	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.00321	0.0192	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—RORA—stomach cancer	0.00314	0.0187	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—KISS1—stomach cancer	0.00313	0.0186	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—KISS1—stomach cancer	0.00309	0.0184	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—RUNX3—stomach cancer	0.00307	0.0183	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HSPD1—stomach cancer	0.00289	0.0172	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.0028	0.0167	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—ANXA1—stomach cancer	0.00274	0.0163	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GAST—stomach cancer	0.00269	0.016	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—RGS2—stomach cancer	0.00269	0.016	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—GADD45A—stomach cancer	0.00261	0.0155	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—KISS1R—stomach cancer	0.00245	0.0146	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.0024	0.0143	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.0024	0.0143	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.00232	0.0139	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—APEX1—stomach cancer	0.00231	0.0138	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HTR1A—stomach cancer	0.00227	0.0135	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1RN—stomach cancer	0.00212	0.0126	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.00207	0.0123	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—F2R—stomach cancer	0.00201	0.012	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR2—stomach cancer	0.00201	0.012	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—F2R—stomach cancer	0.00199	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—BDNF—stomach cancer	0.00199	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—ANXA1—stomach cancer	0.00189	0.0113	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—ANXA1—stomach cancer	0.00187	0.0112	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.0018	0.0107	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—HRH4—stomach cancer	0.00177	0.0105	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.00169	0.0101	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—BDNF—stomach cancer	0.00159	0.00948	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—KISS1—stomach cancer	0.00158	0.0094	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—stomach cancer	0.00152	0.00905	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDK4—stomach cancer	0.0015	0.00893	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.00144	0.00859	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—KISS1R—stomach cancer	0.00138	0.00825	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00135	0.00805	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00133	0.00796	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.0013	0.00775	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KISS1R—stomach cancer	0.00126	0.00749	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00125	0.00748	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.00122	0.00724	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—RHOA—stomach cancer	0.00118	0.00705	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—stomach cancer	0.00107	0.00638	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6R—stomach cancer	0.00105	0.00624	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—stomach cancer	0.00104	0.00619	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR2—stomach cancer	0.00103	0.00613	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—F2R—stomach cancer	0.00102	0.00606	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDKN1B—stomach cancer	0.00101	0.00604	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HRH4—stomach cancer	0.001	0.00596	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—stomach cancer	0.000995	0.00594	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—HTR1A—stomach cancer	0.000989	0.0059	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.000984	0.00587	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCND1—stomach cancer	0.000967	0.00576	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ANXA1—stomach cancer	0.000955	0.0057	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—stomach cancer	0.000939	0.0056	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB1—stomach cancer	0.000925	0.00552	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRH4—stomach cancer	0.000908	0.00541	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.000908	0.00541	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—KISS1—stomach cancer	0.000891	0.00531	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—stomach cancer	0.00083	0.00495	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.00081	0.00483	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KISS1—stomach cancer	0.000809	0.00483	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK3—stomach cancer	0.000797	0.00475	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—stomach cancer	0.000796	0.00475	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—stomach cancer	0.000775	0.00462	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—JUN—stomach cancer	0.000772	0.0046	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RGS2—stomach cancer	0.000766	0.00457	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GAST—stomach cancer	0.000766	0.00457	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK1—stomach cancer	0.000759	0.00452	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—stomach cancer	0.000758	0.00452	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—stomach cancer	0.00075	0.00447	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KISS1R—stomach cancer	0.000742	0.00442	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLI3—stomach cancer	0.000742	0.00442	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—stomach cancer	0.000722	0.00431	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—stomach cancer	0.000709	0.00423	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RBP1—stomach cancer	0.000708	0.00422	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RGS2—stomach cancer	0.000696	0.00415	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GAST—stomach cancer	0.000696	0.00415	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—stomach cancer	0.000674	0.00402	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—stomach cancer	0.000637	0.0038	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—stomach cancer	0.000583	0.00348	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR2—stomach cancer	0.000581	0.00346	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—stomach cancer	0.000578	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WWOX—stomach cancer	0.000577	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—F2R—stomach cancer	0.000574	0.00342	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR1A—stomach cancer	0.000559	0.00333	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ANXA1—stomach cancer	0.00054	0.00322	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WIF1—stomach cancer	0.000536	0.0032	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRH4—stomach cancer	0.000536	0.0032	CbGpPWpGaD
Fosaprepitant—Infestation—Doxorubicin—stomach cancer	0.000529	0.000888	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—stomach cancer	0.000529	0.000888	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR2—stomach cancer	0.000527	0.00314	CbGpPWpGaD
Fosaprepitant—Skin disorder—Docetaxel—stomach cancer	0.000525	0.000881	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	0.000525	0.00088	CcSEcCtD
Fosaprepitant—Oedema—Capecitabine—stomach cancer	0.000524	0.000878	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB1—stomach cancer	0.000523	0.00312	CbGpPWpGaD
Fosaprepitant—Bradycardia—Epirubicin—stomach cancer	0.000523	0.000877	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—F2R—stomach cancer	0.000521	0.00311	CbGpPWpGaD
Fosaprepitant—Infection—Capecitabine—stomach cancer	0.00052	0.000872	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—stomach cancer	0.000519	0.00087	CcSEcCtD
Fosaprepitant—Dizziness—Irinotecan—stomach cancer	0.000517	0.000868	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—stomach cancer	0.000516	0.000865	CcSEcCtD
Fosaprepitant—Shock—Capecitabine—stomach cancer	0.000515	0.000864	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—stomach cancer	0.000514	0.000863	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—stomach cancer	0.000514	0.000863	CcSEcCtD
Fosaprepitant—Nervous system disorder—Capecitabine—stomach cancer	0.000514	0.000861	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—stomach cancer	0.000513	0.00086	CcSEcCtD
Fosaprepitant—Diarrhoea—Fluorouracil—stomach cancer	0.000513	0.00086	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—stomach cancer	0.000512	0.000858	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—stomach cancer	0.000511	0.000857	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—stomach cancer	0.000509	0.000854	CcSEcCtD
Fosaprepitant—Skin disorder—Capecitabine—stomach cancer	0.000509	0.000853	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—HTR1A—stomach cancer	0.000508	0.00303	CbGpPWpGaD
Fosaprepitant—Urinary tract disorder—Epirubicin—stomach cancer	0.000507	0.00085	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Capecitabine—stomach cancer	0.000506	0.000849	CcSEcCtD
Fosaprepitant—Hypotension—Docetaxel—stomach cancer	0.000505	0.000848	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—stomach cancer	0.000505	0.000846	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—stomach cancer	0.000505	0.000846	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—stomach cancer	0.000503	0.000844	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—stomach cancer	0.000498	0.000835	CcSEcCtD
Fosaprepitant—Vomiting—Irinotecan—stomach cancer	0.000497	0.000834	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—stomach cancer	0.000496	0.000831	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—stomach cancer	0.000496	0.000831	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRKAB1—stomach cancer	0.000495	0.00295	CbGpPWpGaD
Fosaprepitant—Mediastinal disorder—Methotrexate—stomach cancer	0.000494	0.000829	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	0.000493	0.00294	CbGpPWpGaD
Fosaprepitant—Rash—Irinotecan—stomach cancer	0.000493	0.000827	CcSEcCtD
Fosaprepitant—Dermatitis—Irinotecan—stomach cancer	0.000493	0.000827	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ANXA1—stomach cancer	0.00049	0.00292	CbGpPWpGaD
Fosaprepitant—Headache—Irinotecan—stomach cancer	0.00049	0.000822	CcSEcCtD
Fosaprepitant—Hypotension—Capecitabine—stomach cancer	0.000489	0.000821	CcSEcCtD
Fosaprepitant—Insomnia—Docetaxel—stomach cancer	0.000489	0.00082	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—stomach cancer	0.000485	0.000814	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—stomach cancer	0.000484	0.000811	CcSEcCtD
Fosaprepitant—Dyspnoea—Docetaxel—stomach cancer	0.000482	0.000809	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—stomach cancer	0.000481	0.000806	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—stomach cancer	0.000481	0.000806	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—stomach cancer	0.00048	0.000805	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—stomach cancer	0.000479	0.000803	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—KISS1—stomach cancer	0.000478	0.00285	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RNF43—stomach cancer	0.000478	0.00285	CbGpPWpGaD
Fosaprepitant—Malnutrition—Methotrexate—stomach cancer	0.000478	0.000801	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—stomach cancer	0.000478	0.000801	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—stomach cancer	0.000477	0.000799	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—stomach cancer	0.000477	0.000799	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—stomach cancer	0.000476	0.000799	CcSEcCtD
Fosaprepitant—Dyspepsia—Docetaxel—stomach cancer	0.000476	0.000798	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.000475	0.00284	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB1—stomach cancer	0.000475	0.00283	CbGpPWpGaD
Fosaprepitant—Insomnia—Capecitabine—stomach cancer	0.000474	0.000794	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—stomach cancer	0.000473	0.000793	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—stomach cancer	0.000472	0.000792	CcSEcCtD
Fosaprepitant—Dermatitis—Fluorouracil—stomach cancer	0.000472	0.000792	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—stomach cancer	0.00047	0.000788	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—stomach cancer	0.000469	0.000787	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	0.000469	0.0028	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	0.000469	0.0028	CbGpPWpGaD
Fosaprepitant—Urinary tract disorder—Doxorubicin—stomach cancer	0.000469	0.000787	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—stomach cancer	0.000468	0.000784	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000467	0.000783	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—stomach cancer	0.000467	0.000783	CcSEcCtD
Fosaprepitant—Dyspnoea—Capecitabine—stomach cancer	0.000467	0.000783	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—stomach cancer	0.000466	0.000782	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—stomach cancer	0.000466	0.00278	CbGpPWpGaD
Fosaprepitant—Angiopathy—Epirubicin—stomach cancer	0.000466	0.000781	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—stomach cancer	0.000466	0.000781	CcSEcCtD
Fosaprepitant—Nausea—Irinotecan—stomach cancer	0.000465	0.000779	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—stomach cancer	0.000464	0.000778	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—stomach cancer	0.000463	0.000776	CcSEcCtD
Fosaprepitant—Pain—Docetaxel—stomach cancer	0.000462	0.000776	CcSEcCtD
Fosaprepitant—Constipation—Docetaxel—stomach cancer	0.000462	0.000776	CcSEcCtD
Fosaprepitant—Dyspepsia—Capecitabine—stomach cancer	0.000461	0.000773	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—stomach cancer	0.000455	0.00272	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Capecitabine—stomach cancer	0.000455	0.000763	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000452	0.000758	CcSEcCtD
Fosaprepitant—Fatigue—Capecitabine—stomach cancer	0.000451	0.000757	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—stomach cancer	0.00045	0.000754	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—stomach cancer	0.000449	0.000753	CcSEcCtD
Fosaprepitant—Pain—Capecitabine—stomach cancer	0.000448	0.000751	CcSEcCtD
Fosaprepitant—Constipation—Capecitabine—stomach cancer	0.000448	0.000751	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—stomach cancer	0.000447	0.00075	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—stomach cancer	0.000447	0.00075	CcSEcCtD
Fosaprepitant—Feeling abnormal—Docetaxel—stomach cancer	0.000446	0.000747	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—stomach cancer	0.000445	0.000746	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—stomach cancer	0.000444	0.000745	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	0.000443	0.00264	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Methotrexate—stomach cancer	0.000443	0.000743	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—stomach cancer	0.000443	0.000743	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Docetaxel—stomach cancer	0.000442	0.000742	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—stomach cancer	0.000441	0.00074	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—stomach cancer	0.000441	0.000739	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—stomach cancer	0.000441	0.000739	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—stomach cancer	0.00044	0.000739	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—stomach cancer	0.000438	0.000734	CcSEcCtD
Fosaprepitant—Feeling abnormal—Capecitabine—stomach cancer	0.000431	0.000724	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—stomach cancer	0.000431	0.000723	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—stomach cancer	0.000431	0.000722	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—stomach cancer	0.00043	0.000721	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—stomach cancer	0.000429	0.00072	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Capecitabine—stomach cancer	0.000428	0.000718	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—stomach cancer	0.000428	0.000718	CcSEcCtD
Fosaprepitant—Abdominal pain—Docetaxel—stomach cancer	0.000428	0.000717	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—stomach cancer	0.000428	0.000717	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FST—stomach cancer	0.000426	0.00254	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—stomach cancer	0.000424	0.00253	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HBEGF—stomach cancer	0.000417	0.00249	CbGpPWpGaD
Fosaprepitant—Cough—Methotrexate—stomach cancer	0.000417	0.000699	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—stomach cancer	0.000416	0.000698	CcSEcCtD
Fosaprepitant—Urticaria—Capecitabine—stomach cancer	0.000416	0.000698	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—stomach cancer	0.000415	0.000696	CcSEcCtD
Fosaprepitant—Body temperature increased—Capecitabine—stomach cancer	0.000414	0.000694	CcSEcCtD
Fosaprepitant—Abdominal pain—Capecitabine—stomach cancer	0.000414	0.000694	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—stomach cancer	0.000414	0.000694	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—stomach cancer	0.000414	0.000694	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—stomach cancer	0.000413	0.000693	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GAST—stomach cancer	0.000411	0.00245	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RGS2—stomach cancer	0.000411	0.00245	CbGpPWpGaD
Fosaprepitant—Flatulence—Doxorubicin—stomach cancer	0.000408	0.000683	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	0.000407	0.00243	CbGpPWpGaD
Fosaprepitant—Chest pain—Methotrexate—stomach cancer	0.000407	0.000682	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—stomach cancer	0.000405	0.000679	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000404	0.000677	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—stomach cancer	0.000403	0.000676	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—stomach cancer	0.000402	0.000674	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—stomach cancer	0.000401	0.000672	CcSEcCtD
Fosaprepitant—Hypersensitivity—Docetaxel—stomach cancer	0.000398	0.000668	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—stomach cancer	0.000398	0.000667	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—stomach cancer	0.000395	0.000662	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—stomach cancer	0.000393	0.000659	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—stomach cancer	0.00039	0.000654	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—stomach cancer	0.00039	0.000654	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGG—stomach cancer	0.00039	0.00232	CbGpPWpGaD
Fosaprepitant—Asthenia—Docetaxel—stomach cancer	0.000388	0.000651	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—stomach cancer	0.000387	0.000649	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—stomach cancer	0.000386	0.000647	CcSEcCtD
Fosaprepitant—Hypersensitivity—Capecitabine—stomach cancer	0.000386	0.000647	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—stomach cancer	0.000385	0.00229	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Doxorubicin—stomach cancer	0.000384	0.000644	CcSEcCtD
Fosaprepitant—Pruritus—Docetaxel—stomach cancer	0.000383	0.000642	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—stomach cancer	0.000382	0.000641	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—stomach cancer	0.000382	0.000641	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—stomach cancer	0.000381	0.000638	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—stomach cancer	0.000379	0.000636	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—stomach cancer	0.000379	0.000635	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000378	0.000634	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PPP2R1A—stomach cancer	0.000377	0.00225	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	0.000377	0.00225	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Methotrexate—stomach cancer	0.000377	0.000632	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—stomach cancer	0.000376	0.000631	CcSEcCtD
Fosaprepitant—Asthenia—Capecitabine—stomach cancer	0.000376	0.00063	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRKAA1—stomach cancer	0.000375	0.00224	CbGpPWpGaD
Fosaprepitant—Malaise—Doxorubicin—stomach cancer	0.000373	0.000625	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—stomach cancer	0.000372	0.000624	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—stomach cancer	0.000371	0.000622	CcSEcCtD
Fosaprepitant—Pruritus—Capecitabine—stomach cancer	0.00037	0.000621	CcSEcCtD
Fosaprepitant—Diarrhoea—Docetaxel—stomach cancer	0.00037	0.000621	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—stomach cancer	0.000365	0.000613	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—stomach cancer	0.000365	0.000612	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—stomach cancer	0.000365	0.000612	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—stomach cancer	0.000364	0.000611	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—stomach cancer	0.000363	0.00061	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—stomach cancer	0.000362	0.000608	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RBP4—stomach cancer	0.000362	0.00216	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—stomach cancer	0.000362	0.00216	CbGpPWpGaD
Fosaprepitant—Cough—Doxorubicin—stomach cancer	0.000361	0.000605	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	0.000361	0.00215	CbGpPWpGaD
Fosaprepitant—Shock—Epirubicin—stomach cancer	0.000359	0.000602	CcSEcCtD
Fosaprepitant—Diarrhoea—Capecitabine—stomach cancer	0.000358	0.000601	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—stomach cancer	0.000358	0.0006	CcSEcCtD
Fosaprepitant—Dizziness—Docetaxel—stomach cancer	0.000358	0.0006	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—stomach cancer	0.000357	0.000599	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—stomach cancer	0.000354	0.000594	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—stomach cancer	0.000353	0.000591	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—stomach cancer	0.000353	0.000591	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—stomach cancer	0.000352	0.000591	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—stomach cancer	0.000351	0.000588	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.00035	0.000586	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—stomach cancer	0.000348	0.000583	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—stomach cancer	0.000348	0.000583	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—stomach cancer	0.000347	0.000581	CcSEcCtD
Fosaprepitant—Dizziness—Capecitabine—stomach cancer	0.000346	0.000581	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—stomach cancer	0.000344	0.000578	CcSEcCtD
Fosaprepitant—Vomiting—Docetaxel—stomach cancer	0.000344	0.000577	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—stomach cancer	0.000343	0.000575	CcSEcCtD
Fosaprepitant—Rash—Docetaxel—stomach cancer	0.000341	0.000572	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—stomach cancer	0.000341	0.000572	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—stomach cancer	0.000341	0.000571	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—stomach cancer	0.000339	0.000568	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—stomach cancer	0.000339	0.000568	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—stomach cancer	0.000338	0.000566	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—stomach cancer	0.000338	0.000566	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000337	0.000564	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—stomach cancer	0.000336	0.000564	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—stomach cancer	0.000335	0.000562	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—stomach cancer	0.000333	0.000559	CcSEcCtD
Fosaprepitant—Vomiting—Capecitabine—stomach cancer	0.000333	0.000558	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—stomach cancer	0.000332	0.000557	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—stomach cancer	0.000331	0.000555	CcSEcCtD
Fosaprepitant—Rash—Capecitabine—stomach cancer	0.00033	0.000554	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—stomach cancer	0.00033	0.000553	CcSEcCtD
Fosaprepitant—Dermatitis—Capecitabine—stomach cancer	0.00033	0.000553	CcSEcCtD
Fosaprepitant—Headache—Capecitabine—stomach cancer	0.000328	0.00055	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—stomach cancer	0.000328	0.00055	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—stomach cancer	0.000326	0.000547	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—stomach cancer	0.000325	0.000545	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—stomach cancer	0.000324	0.000544	CcSEcCtD
Fosaprepitant—Nausea—Docetaxel—stomach cancer	0.000321	0.000539	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—stomach cancer	0.000321	0.000539	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—stomach cancer	0.000321	0.000539	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—stomach cancer	0.000319	0.000535	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—stomach cancer	0.000317	0.000532	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—stomach cancer	0.000315	0.000529	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000315	0.000528	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—stomach cancer	0.000315	0.000527	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—stomach cancer	0.000312	0.000523	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—stomach cancer	0.000312	0.000523	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HSPB1—stomach cancer	0.000312	0.00186	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR2—stomach cancer	0.000312	0.00186	CbGpPWpGaD
Fosaprepitant—Nausea—Capecitabine—stomach cancer	0.000311	0.000522	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—stomach cancer	0.00031	0.000519	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—stomach cancer	0.000308	0.000517	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—stomach cancer	0.000308	0.000517	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—F2R—stomach cancer	0.000308	0.00184	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BMP2—stomach cancer	0.000308	0.00184	CbGpPWpGaD
Fosaprepitant—Insomnia—Doxorubicin—stomach cancer	0.000305	0.000512	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—AKR1C3—stomach cancer	0.000303	0.00181	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Doxorubicin—stomach cancer	0.000301	0.000505	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—stomach cancer	0.000301	0.000504	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—stomach cancer	0.0003	0.000503	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HTR1A—stomach cancer	0.0003	0.00179	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Epirubicin—stomach cancer	0.000298	0.0005	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—stomach cancer	0.000297	0.000498	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—stomach cancer	0.000293	0.000492	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000291	0.000489	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—stomach cancer	0.000291	0.000488	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCB—stomach cancer	0.00029	0.00173	CbGpPWpGaD
Fosaprepitant—Urticaria—Epirubicin—stomach cancer	0.00029	0.000486	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ANXA1—stomach cancer	0.00029	0.00173	CbGpPWpGaD
Fosaprepitant—Constipation—Doxorubicin—stomach cancer	0.000289	0.000484	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—stomach cancer	0.000289	0.000484	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—stomach cancer	0.000288	0.000484	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—stomach cancer	0.000288	0.000484	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—stomach cancer	0.000287	0.000482	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ADRB1—stomach cancer	0.00028	0.00167	CbGpPWpGaD
Fosaprepitant—Asthenia—Methotrexate—stomach cancer	0.00028	0.000469	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—stomach cancer	0.000278	0.000466	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000276	0.000463	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—stomach cancer	0.000276	0.000463	CcSEcCtD
Fosaprepitant—Hypersensitivity—Epirubicin—stomach cancer	0.000269	0.000451	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—stomach cancer	0.000268	0.00045	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RPS6—stomach cancer	0.000268	0.0016	CbGpPWpGaD
Fosaprepitant—Abdominal pain—Doxorubicin—stomach cancer	0.000267	0.000447	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—stomach cancer	0.000267	0.000447	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—stomach cancer	0.000267	0.000447	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCB—stomach cancer	0.000264	0.00157	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6ST—stomach cancer	0.000263	0.00157	CbGpPWpGaD
Fosaprepitant—Asthenia—Epirubicin—stomach cancer	0.000262	0.000439	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—stomach cancer	0.000258	0.000433	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—stomach cancer	0.000258	0.000432	CcSEcCtD
Fosaprepitant—Diarrhoea—Epirubicin—stomach cancer	0.00025	0.000419	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—stomach cancer	0.000249	0.000417	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—stomach cancer	0.000248	0.000416	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HBEGF—stomach cancer	0.000246	0.00147	CbGpPWpGaD
Fosaprepitant—Rash—Methotrexate—stomach cancer	0.000246	0.000412	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—stomach cancer	0.000246	0.000412	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—stomach cancer	0.000244	0.00041	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—stomach cancer	0.000242	0.000406	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—stomach cancer	0.000241	0.000405	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—stomach cancer	0.000239	0.0004	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—IL6R—stomach cancer	0.000234	0.0014	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RHOA—stomach cancer	0.000233	0.00139	CbGpPWpGaD
Fosaprepitant—Vomiting—Epirubicin—stomach cancer	0.000232	0.000389	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—stomach cancer	0.000232	0.000388	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—stomach cancer	0.000231	0.000387	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—stomach cancer	0.00023	0.000386	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—stomach cancer	0.00023	0.000385	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—stomach cancer	0.000229	0.000383	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—stomach cancer	0.000227	0.00136	CbGpPWpGaD
Fosaprepitant—Dizziness—Doxorubicin—stomach cancer	0.000223	0.000374	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PPP2R1A—stomach cancer	0.000223	0.00133	CbGpPWpGaD
Fosaprepitant—Nausea—Epirubicin—stomach cancer	0.000217	0.000363	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—stomach cancer	0.000215	0.00036	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—stomach cancer	0.000213	0.000357	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—stomach cancer	0.000213	0.000357	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—RHOA—stomach cancer	0.000212	0.00126	CbGpPWpGaD
Fosaprepitant—Headache—Doxorubicin—stomach cancer	0.000211	0.000355	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SMAD4—stomach cancer	0.000207	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—stomach cancer	0.000205	0.00122	CbGpPWpGaD
Fosaprepitant—Nausea—Doxorubicin—stomach cancer	0.0002	0.000336	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FYN—stomach cancer	0.000196	0.00117	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—stomach cancer	0.000186	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGFR2—stomach cancer	0.000184	0.0011	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS2—stomach cancer	0.000169	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CAV1—stomach cancer	0.000164	0.000976	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA1—stomach cancer	0.000163	0.000974	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCB—stomach cancer	0.000156	0.000929	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6ST—stomach cancer	0.000155	0.000925	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APC—stomach cancer	0.000149	0.000889	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK3—stomach cancer	0.000143	0.000851	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6R—stomach cancer	0.000138	0.000825	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK1—stomach cancer	0.000136	0.00081	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—stomach cancer	0.000136	0.00081	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—stomach cancer	0.00013	0.000774	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—stomach cancer	0.00013	0.000773	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KRAS—stomach cancer	0.000128	0.000765	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RHOA—stomach cancer	0.000125	0.000746	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—stomach cancer	0.000124	0.000738	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—stomach cancer	0.000118	0.000703	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB2—stomach cancer	0.000116	0.00069	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—stomach cancer	0.00011	0.000654	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRAS—stomach cancer	0.000109	0.00065	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1B—stomach cancer	0.000107	0.000639	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—stomach cancer	0.000104	0.000622	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCND1—stomach cancer	0.000102	0.00061	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JUN—stomach cancer	0.000102	0.000608	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—stomach cancer	9.93e-05	0.000592	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1A—stomach cancer	9.89e-05	0.00059	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK8—stomach cancer	9.66e-05	0.000576	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—stomach cancer	8.91e-05	0.000532	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—stomach cancer	8.83e-05	0.000526	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK3—stomach cancer	8.43e-05	0.000503	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—stomach cancer	8.2e-05	0.000489	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK1—stomach cancer	8.02e-05	0.000478	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—stomach cancer	8.02e-05	0.000478	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KRAS—stomach cancer	7.58e-05	0.000452	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—stomach cancer	6.96e-05	0.000415	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—stomach cancer	6.74e-05	0.000402	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRAS—stomach cancer	6.44e-05	0.000384	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—stomach cancer	6.17e-05	0.000368	CbGpPWpGaD
